Company news

hVIVO plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Launch of full suite of hLAB standalone services

September 30, 2024

Notice of results

August 20, 2024

Euronext cancellation

August 5, 2024

Change of registered address

July 2, 2024

Capital Markets Day & Notice of trading update

July 2, 2024

Influenza 2b field study contract

July 2, 2024

£2.5m contract for Omicron characterisation study

June 3, 2024

Annual Report & Notice of AGM

April 15, 2024

HVIVO achieves record revenue and initiates dividend policy following successful year

April 9, 2024

Long Term Incentive Plan / PDMR Notification

February 15, 2024

Result of Secondary Placing

February 14, 2024

Proposed Secondary Placing of Ordinary Shares

February 14, 2024

Broker change

January 8, 2024

£6.3m HRV contract signed with biotech client

January 2, 2024

£16.8m RSV contract & Trading ahead of guidance

December 13, 2023

Positive results from flu human challenge study

October 5, 2023

Exercise of Warrants

September 1, 2023

Plans for a new larger state-of-the-art facility

August 29, 2023

Flu B challenge model

July 25, 2023

hMPV human challenge model

June 28, 2023

Director dealings

June 14, 2023

Annual Report and Notice of AGM

April 28, 2023

FDA Breakthrough and Fast Track for US biotech

April 26, 2023

HVIVO reveals audited results for "transformational" 2022

April 25, 2023

Presentation at World Vaccine Congress

March 29, 2023

Omicron human challenge model update

March 16, 2023

Second Price Monitoring Extn

February 6, 2023

HVIVO announces "record results" for 2022

January 26, 2023

Price Monitoring Extension

January 25, 2023

EUR3.2m Venn contract with global pharma client

January 17, 2023

£5.2m RSV contract and Notice of Trading update

January 4, 2023

Imutex Phase I data published

December 19, 2022

hVIVO hails growing contract values after winni...

November 14, 2022

£13.6m RSV antiviral contract

November 10, 2022

Change of name to hVIVO plc effective

October 25, 2022

Capital Markets Day

October 20, 2022

CFO appointment & change of Board roles

October 18, 2022

Positive in vitro results for FLU-v published

September 30, 2022

Upcoming Scientific Presentations

September 27, 2022

Comment regarding press speculation

September 15, 2022

Interim results and trading update

September 8, 2022

CAP accreditation

September 1, 2022

£10.4m contract with existing Big Pharma client

August 22, 2022

£6.2m Influenza human challenge study contract

August 4, 2022

Omicron human challenge model

June 30, 2022

£7.2m RSV human challenge study contract

June 14, 2022

Board appointment amendment

June 10, 2022

Board appointment

June 8, 2022

GBP14.7m influenza contract signed

June 1, 2022

Completion of Nominated Adviser due diligence

May 26, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.